Suggested remit: To appraise the clinical and cost effectiveness of masitinib with riluzole within its marketing authorisation for treating amyotrophic lateral sclerosis in adults.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6257
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 January 2024 - 16 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6257 |
| 06 February 2024 | Note - Note added to the project documents |
| 19 January 2024 | In progress. Scoping commencing |
| 16 June 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual